Cingulate Inc. (CING) vs iBio, Inc. (IBIO)

A side-by-side comparison of Cingulate Inc. and iBio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CING

Cingulate Inc.

$66M

$4.87HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT

IBIO

iBio, Inc.

$68M

$1.07HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT

Total return — CING vs IBIO

growth of $100 · dividends reinvested · last 5y

CING -99.6% (-66.1%/yr)IBIO -99.7% (-68.4%/yr)CING compounded faster over this window

CING IBIO

CING vs IBIO: by the numbers

•IBIO is the larger company ($68M vs $66M market cap).
•Both run net losses; CING's is the smaller (0.00% vs -33044.00% net margin).

Metrics side by side

Valuation

Metric	CING	IBIO
P/S ratio	N/A	684.87
P/B ratio	2.80	0.80
EV / EBITDA	0.22	N/A

Profitability

Metric	CING	IBIO
Gross margin	0.00%	100.00%
Operating margin	0.00%	-35141.00%
Net margin	0.00%	-33044.00%
ROE	-122.71%	-38.55%
ROIC	-83.74%	-40.22%

Growth (annualized)

Metric	CING	IBIO
Revenue CAGR (5Y)	N/A	-46.91%
Total return CAGR (5Y)	N/A	-70.43%

Go deeper

Full CING analysis Full IBIO analysis Interactive comparison tool

Dig into the metrics

Cingulate ROE iBio ROE Cingulate operating margin iBio operating margin Cingulate revenue growth iBio revenue growth Cingulate free cash flow iBio free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.